Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
Kyo TogashiShingo HatakeyamaTohru YoneyamaTomoko HamayaTakuma NaritaNaoki FujitaHiromichi IwamuraTeppei OkamotoHayato YamamotoTakahiro YoneyamaYasuhiro HashimotoChikara OhyamaPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Patients with urothelial carcinoma or renal cell carcinoma exhibited an adequate antibody response to the BNT162b2 vaccine. Active anticancer therapy was not significantly associated with seropositivity following vaccination with severe acute respiratory syndrome coronavirus 2 BNT162b2 in patients with urothelial carcinoma and renal cell carcinoma.